Short‐ and long‐term outcomes in diabetes patients undergoing percutaneous coronary intervention with bivalirudin compared with heparin and glycoprotein IIb/IIIA inhibitors: A meta‐analysis of randomized trials

By  

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol. 86, Iss. 3, 2015-09 ,pp. : 364-375

John Wiley & Sons Inc

Access to resources Recommend Favorite

Use of Glycoprotein IIb/IIIa Inhibitors in Patients with Acute Coronary Syndromes Undergoing Coronary Revascularization

By  

Pathophysiology of Haemostasis and Thrombosis, Vol. 29, Iss. 1, 2004-11 ,pp. : 69-71

Karger

Access to resources Recommend Favorite

Diabetes is not sufficient justification for IIb/IIIa use in percutaneous coronary intervention

By  

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol. 86, Iss. 3, 2015-09 ,pp. : 376-377

John Wiley & Sons Inc

Access to resources Recommend Favorite

Influence of Some Cardiovascular Risk Factors on the Expression of Platelet Glycoprotein IIb/IIIa Receptors in Patients with Myocardial Infarction Treated with Antiplatelet Drugs under Primary Percutaneous Coronary Intervention

By Konopka Anna  

Molecular Diagnosis & Therapy, Vol. 13, Iss. 6, 2009-12 ,pp. : 375-382

Adis International

Access to resources Recommend Favorite

Glycoprotein IIb/IIIa Receptor Inhibition with Abciximab during Percutaneous Coronary Interventions Increases the Risk of Bleeding in Patients with Impaired Renal Function

By  

Cardiology, Vol. 111, Iss. 4, 2008-04 ,pp. : 247-253

Karger

Access to resources Recommend Favorite